Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

View All Documentation

L6545

Sigma-Aldrich

Letrozole

≥98% (HPLC), powder, non-steroidal aromatase inhibitor

Synonyme(s) :

4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Formule empirique (notation de Hill):
C17H11N5
Numéro CAS:
112809-51-5
Poids moléculaire :
285.30
Numéro MDL:
MFCD00866241
Code UNSPSC :
51111800
ID de substance PubChem :
329817641
Nomenclature NACRES :
NA.77

product name

Letrozole, ≥98% (HPLC)

Niveau de qualité

100

Pureté

≥98% (HPLC)

Forme

powder

Couleur

white to off-white

Solubilité

DMSO: >50 mg/mL

Auteur

Novartis

Température de stockage

2-8°C

Chaîne SMILES 

N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3

InChI

1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H

Clé InChI

HPJKCIUCZWXJDR-UHFFFAOYSA-N

Informations sur le gène

human ... CYP19A1(1588)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Letrozole has been used:
  • in organoid growth assay to determine its inhibitory capacity(48)
  • to investigate steroid receptor coactivator-1 (SRC-1) mediated endogenous estrogen regulation of hippocampal PSD-95(49)
  • to determine its effects on tumor-induced hyperalgesia(50)
  • for hormonal manipulation in rats(51)
  • to study its effects on lipocalin-2 (Lcn2)(52)
  • to determine its effects on mechanical hyperalgesia and aromatase expression(53)

Actions biochimiques/physiologiques

Letrozole acts as an adjuvant agent and is used to treat breast cancer.
Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.

Caractéristiques et avantages

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361fd,H373

Classification des risques

Repr. 2 - STOT RE 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 5

1 of 5

USP

USP

1356982

Letrozole Related Compound A

PF-05212384 ≥98% (HPLC)

Sigma-Aldrich

PZ0281

PF-05212384

PHTPP ≥98% (HPLC)

Sigma-Aldrich

SML1355

PHTPP

Capecitabine ≥98% (HPLC)

Sigma-Aldrich

SML0653

Capecitabine

Exemestane Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1634

Exemestane

Drugs for Pregnant and Lactating Women E-Book (2009)
Natalia Lagunas et al.
Frontiers in neuroanatomy, 16, 902218-902218 (2022-07-12)
Sex steroid hormones, such as androgens and estrogens, are known to exert organizational action at perinatal periods and activational effects during adulthood on the brain and peripheral tissues. These organizational effects are essential for the establishment of biological axes responsible
Bianca Posocco et al.
PloS one, 15(2), e0228822-e0228822 (2020-02-08)
A novel LC-MS/MS method was developed for the quantification of the new cyclin dependent kinase inhibitors (CDKIs) palbociclib and ribociclib and the aromatase inhibitor letrozole used in combinatory regimen. The proposed method is appropriate to be applied in clinical practice
Lauren D Otto et al.
Frontiers in oncology, 12, 798704-798704 (2022-04-12)
Breast cancer is one of the most common diseases in the United States with 1 in 8 women developing the disease in her lifetime. Women who develop breast cancer are often post-menopausal and undergo a complex sequence of treatments including surgery, chemotherapy, and aromatase inhibitor therapy. Both independently and
Dennis C Sgroi et al.
Journal of the National Cancer Institute, 105(14), 1036-1042 (2013-07-03)
Biomarkers to optimize extended adjuvant endocrine therapy for women with estrogen receptor (ER)-positive breast cancer are limited. The HOXB13/IL17BR (H/I) biomarker predicts recurrence risk in ER-positive, lymph node-negative breast cancer patients. H/I was evaluated in MA.17 trial for prognostic performance
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique